Expression of LMO2 is associated with t(14;18)/IGH-BCL2 fusion but not BCL6 translocations in diffuse large B-cell lymphoma

David K. Durnick, Mark E. Law, Matthew J. Maurer, Yasodha Natkunam, Ronald Levy, Izidore S. Lossos, Paul J. Kurtin, Ellen D. McPhail

Research output: Contribution to journalArticle

7 Scopus citations


Diffuse large B-cell lymphoma (DLBCL) can be separated for prognostic purposes using gene expression profiling (GEP) into 2 subgroups: germinal center B-cell (GCB) and activated B-cell phenotypes. However, GEP is impractical for routine clinical use, and immunophenotyping is an imperfect surrogate. Therefore, we studied the relationship between expression of the purported germinal center marker LMO2 and the presence of IGH-BCL2 fusions, BCL6 translocations, and LMO2 translocations. In addition, we investigated the usefulness of LMO2 expression as a marker of GCB subtype in DLBCL. Immunohistochemical and fluorescence in situ hybridization studies were successfully performed on 101 cases of de novo DLBCL that had been incorporated into a tissue microarray. There was a statistically significant association between IGH-BCL2 fusion and LMO2 protein expression (P = .02) but not between BCL6 translocations and LMO2 expression. LMO2 translocations were not identified. Although uncommon, all cases that had both IGH-BCL2 fusion and BCL6 translocations expressed LMO2. The findings suggest LMO2 as a potential marker for the GCB phenotype.

Original languageEnglish (US)
Pages (from-to)278-281
Number of pages4
JournalAmerican journal of clinical pathology
Issue number2
StatePublished - Aug 1 2010



  • BCL6
  • Diffuse large B-cell lymphoma
  • LMO2
  • t(14;18)IgH/BCL2

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this